Barely Significant
← all excerpts

Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.

J Inflamm Res · 2026 · PMC13289661 · PMID 42345003

Europe PMCDOI
1
hedged sentence
0.0390
closest p · 0.8× alpha
0.0390
boldest claim

The sentences

nominally significantP =0.0390actually significant
69 In the phase 3 CUPID B trial that investigated patients with CSU who were refractory to 3 months of omalizumab therapy, a nominally significant reduction in UAS7 from baseline compared with placebo (−14.4 vs −8.5; P =0.0390) was observed at week 24.

also in 3,108 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.